

Ravindra K Gupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2275191/publications.pdf>

Version: 2024-02-01

108
papers

14,890
citations

81900

39
h-index

27406

106
g-index

140
all docs

140
docs citations

140
times ranked

19117
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	28.6	2,650
2	SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. <i>Nature</i> , 2021, 599, 114-119.	27.8	1,041
3	SARS-CoV-2 evolution during treatment of chronic infection. <i>Nature</i> , 2021, 592, 277-282.	27.8	802
4	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	16.3	778
5	The "Silent" Global Burden of Congenital Cytomegalovirus. <i>Clinical Microbiology Reviews</i> , 2013, 26, 86-102.	13.6	771
6	Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. <i>Nature</i> , 2022, 603, 706-714.	27.8	756
7	Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. <i>Nature</i> , 2021, 593, 136-141.	27.8	648
8	Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. <i>Nature</i> , 2021, 596, 417-422.	27.8	549
9	HIV-1 remission following CCR5 ^{Δ32/Δ32} haematopoietic stem-cell transplantation. <i>Nature</i> , 2019, 568, 244-248.	27.8	447
10	Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. <i>Cell Reports</i> , 2021, 35, 109292.	6.4	375
11	Global trends in antiretroviral resistance in treatment-naïve individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. <i>Lancet, The</i> , 2012, 380, 1250-1258.	13.7	324
12	HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. <i>Lancet Infectious Diseases, The</i> , 2018, 18, 346-355.	9.1	290
13	Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. <i>Immunity</i> , 2021, 54, 1257-1275.e8.	14.3	230
14	Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. <i>Science</i> , 2021, 374, 995-999.	12.6	230
15	Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 565-575.	9.1	217
16	Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2009, 9, 409-417.	9.1	216
17	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	6.4	200
18	The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. <i>Cell</i> , 2021, 184, 5189-5200.e7.	28.9	186

#	ARTICLE	IF	CITATIONS
19	Mutation of a Single Residue Renders Human Tetherin Resistant to HIV-1 Vpu-Mediated Depletion. <i>PLoS Pathogens</i> , 2009, 5, e1000443.	4.7	171
20	Emergence of Drug Resistance in HIV Type 1 "Infected Patients after Receipt of First-Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials. <i>Clinical Infectious Diseases</i> , 2008, 47, 712-722.	5.8	165
21	Will SARS-CoV-2 variants of concern affect the promise of vaccines?. <i>Nature Reviews Immunology</i> , 2021, 21, 340-341.	22.7	162
22	Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20889-20894.	7.1	151
23	Evidence for HIV-1 cure after CCR5 Δ 32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. <i>Lancet HIV</i> , 2020, 7, e340-e347.	4.7	151
24	Mumps and the UK epidemic 2005. <i>BMJ: British Medical Journal</i> , 2005, 330, 1132-1135.	2.3	137
25	SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion. <i>Journal of Infectious Diseases</i> , 2021, 224, 989-994.	4.0	136
26	Emergence of HIV Drug Resistance During First- and Second-Line Antiretroviral Therapy in Resource-Limited Settings. <i>Journal of Infectious Diseases</i> , 2013, 207, S49-S56.	4.0	117
27	Bacterial Pneumonia and Pandemic Influenza Planning. <i>Emerging Infectious Diseases</i> , 2008, 14, 1187-1192.	4.3	109
28	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV</i> , 2019, 6, e116-e127.	4.7	84
29	Selection Analysis Identifies Clusters of Unusual Mutational Changes in Omicron Lineage BA.1 That Likely Impact Spike Function. <i>Molecular Biology and Evolution</i> , 2022, 39, .	8.9	84
30	A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. <i>EMBO Journal</i> , 2017, 36, 604-616.	7.8	82
31	COVID-19 vaccine breakthrough infections. <i>Science</i> , 2021, 374, 1561-1562.	12.6	81
32	The HUSH complex is a gatekeeper of type I interferon through epigenetic regulation of LINE-1s. <i>Nature Communications</i> , 2020, 11, 5387.	12.8	79
33	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. <i>PLoS ONE</i> , 2015, 10, e0145772.	2.5	72
34	Full-length HIV-1 Gag determines protease inhibitor susceptibility within in-vitro assays. <i>Aids</i> , 2010, 24, 1651-1655.	2.2	66
35	HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. <i>Retrovirology</i> , 2011, 8, 103.	2.0	61
36	Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant. <i>Cell Reports Medicine</i> , 2020, 1, 100099.	6.5	61

#	ARTICLE	IF	CITATIONS
37	Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 296-304.	9.1	58
38	Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase. <i>Nature Communications</i> , 2020, 11, 5922.	12.8	55
39	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000â€“2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , 2019, 9, 26-34.	7.1	51
40	Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and Implementation Study. <i>Cell Reports Medicine</i> , 2020, 1, 100062.	6.5	47
41	Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study. <i>Lancet HIV,the</i> , 2020, 7, e620-e628.	4.7	46
42	<scp>DNA</scp> damage induced by topoisomerase inhibitors activates <scp>SAMHD</scp> 1 and blocks <scp>HIV</scp> â€“1 infection of macrophages. <i>EMBO Journal</i> , 2018, 37, 50-62.	7.8	44
43	Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines. <i>Lancet HIV,the</i> , 2020, 7, e193-e200.	4.7	41
44	Performance Evaluation of the SAMBA II SARS-CoV-2 Test for Point-of-Care Detection of SARS-CoV-2. <i>Journal of Clinical Microbiology</i> , 2020, 59, .	3.9	38
45	Virological Outcomes of Second-line Protease Inhibitorâ€“Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis. <i>Clinical Infectious Diseases</i> , 2017, 64, 1006-1016.	5.8	37
46	Timing of monoclonal antibody for seasonal RSV prophylaxis in the United Kingdom. <i>Epidemiology and Infection</i> , 2007, 135, 159-162.	2.1	36
47	Causes and Consequences of Incomplete HIV RNA Suppression in Clinical Trials. <i>HIV Clinical Trials</i> , 2009, 10, 289-298.	2.0	36
48	Macrophages. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 561-566.	3.1	36
49	High Rate of HIV Resuppression After Viral Failure on First-line Antiretroviral Therapy in the Absence of Switch to Second-line Therapy. <i>Clinical Infectious Diseases</i> , 2014, 58, 1023-1026.	5.8	36
50	Diffuse White Matter Signal Abnormalities on Magnetic Resonance Imaging Are Associated With Human Immunodeficiency Virus Type 1 Viral Escape in the Central Nervous System Among Patients With Neurological Symptoms. <i>Clinical Infectious Diseases</i> , 2017, 64, 1059-1065.	5.8	36
51	Failure to seroconvert after two doses of BNT162b2 SARS-CoV-2 vaccine in a patient with uncontrolled HIV. <i>Lancet HIV,the</i> , 2021, 8, e317-e318.	4.7	36
52	K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. <i>Aids</i> , 2005, 19, 1916-1919.	2.2	31
53	HIV resistance and the developing world. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 510-517.	2.5	31
54	Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation. <i>PLoS ONE</i> , 2017, 12, e0181357.	2.5	31

#	ARTICLE	IF	CITATIONS
55	Oseltamivir Resistance in Influenza A (H5N1) Infection. <i>New England Journal of Medicine</i> , 2006, 354, 1423-1424.	27.0	29
56	Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited Settings. <i>Journal of Infectious Diseases</i> , 2013, 207, S78-S84.	4.0	29
57	TLR4-Mediated Pathway Triggers Interferon-Independent G0 Arrest and Antiviral SAMHD1 Activity in Macrophages. <i>Cell Reports</i> , 2020, 30, 3972-3980.e5.	6.4	29
58	B cell receptor repertoire kinetics after SARS-CoV-2 infection and vaccination. <i>Cell Reports</i> , 2022, 38, 110393.	6.4	29
59	Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration. <i>EBioMedicine</i> , 2017, 18, 225-235.	6.1	28
60	Rapid inactivation of SARS-CoV-2 by titanium dioxide surface coating. <i>Wellcome Open Research</i> , 2021, 6, 56.	1.8	28
61	Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1345-1347.	9.1	26
62	A Tail of Tetherin: How Pandemic HIV-1 Conquered the World. <i>Cell Host and Microbe</i> , 2009, 6, 393-395.	11.0	25
63	T cell derived HIV-1 is present in the CSF in the face of suppressive antiretroviral therapy. <i>PLoS Pathogens</i> , 2021, 17, e1009871.	4.7	25
64	Management of paediatric HIV-1 resistance. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 256-263.	3.1	21
65	Impact of the N348I Mutation in HIV-1 Reverse Transcriptase on Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Non-Subtype B HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 1806-1809.	3.2	21
66	Oral Antiretroviral Drugs as Public Health Tools for HIV Prevention: Global Implications for Adherence, Drug Resistance, and the Success of HIV Treatment Programs. <i>Journal of Infectious Diseases</i> , 2013, 207, S101-S106.	4.0	21
67	Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era. <i>Aids</i> , 2021, 35, S127-S135.	2.2	21
68	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. <i>PLoS ONE</i> , 2022, 17, e0263328.	2.5	21
69	Genome-Wide Association Study of HIV Whole Genome Sequences Validated using Drug Resistance. <i>PLoS ONE</i> , 2016, 11, e0163746.	2.5	20
70	Drug Resistance in Human Immunodeficiency Virus Type-1 Infected Zambian Children Using Adult Fixed Dose Combination Stavudine, Lamivudine, and Nevirapine. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, e57-e62.	2.0	19
71	Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I. <i>Journal of Infectious Diseases</i> , 2020, 222, 1108-1116.	4.0	19
72	Immune evasion activities of accessory proteins Vpu, Nef and Vif are conserved in acute and chronic HIV-1 infection. <i>Virology</i> , 2015, 482, 72-78.	2.4	18

#	ARTICLE	IF	CITATIONS
73	HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 243-248.	3.0	18
74	Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. <i>Clinical Infectious Diseases</i> , 2015, 61, 120-128.	5.8	17
75	Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial. <i>PLoS ONE</i> , 2015, 10, e0137834.	2.5	17
76	Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag-protease genes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3340-3348.	3.0	16
77	HIV Cerebrospinal Fluid Escape and Neurocognitive Pathology in the Era of Combined Antiretroviral Therapy: What Lies Beneath the Tip of the Iceberg in Sub-Saharan Africa?. <i>Brain Sciences</i> , 2018, 8, 190.	2.3	16
78	Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1032-1037.	1.1	15
79	Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1450-1455.	3.0	15
80	Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 473-479.	3.0	15
81	Cell Cycle Regulation in Macrophages and Susceptibility to HIV-1. <i>Viruses</i> , 2020, 12, 839.	3.3	14
82	Public Understanding of Pandemic Influenza, United Kingdom. <i>Emerging Infectious Diseases</i> , 2006, 12, 1620-1621.	4.3	12
83	The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains. <i>Retrovirology</i> , 2011, 8, 31.	2.0	12
84	Virological efficacy of PI monotherapy for HIV-1 in clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3228-3234.	3.0	12
85	High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1575-1579.	3.0	12
86	Vpx complementation of non-macrophage tropic R5 viruses reveals robust entry of infectious HIV-1 cores into macrophages. <i>Retrovirology</i> , 2014, 11, 25.	2.0	11
87	<i>In Vivo</i> Emergence of a Novel Protease Inhibitor Resistance Signature in HIV-1 Matrix. <i>MBio</i> , 2020, 11, .	4.1	11
88	Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency. <i>Scientific Reports</i> , 2016, 6, 38153.	3.3	10
89	NO EVIDENCE OF CARDIOTOXICITY OF ATOVAQUONE-PROGUANIL ALONE OR IN COMBINATION WITH ARTESUNATE. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 267-268.	1.4	10
90	The arrival of untreatable multidrug-resistant HIV-1 in sub-Saharan Africa. <i>Aids</i> , 2014, 28, 1373-1374.	2.2	9

#	ARTICLE	IF	CITATIONS
91	Transmission of B.1.617.2 Delta variant between vaccinated healthcare workers. <i>Scientific Reports</i> , 2022, 12, .	3.3	9
92	Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, , .	3.0	8
93	Rapid inactivation of SARS-CoV-2 by titanium dioxide surface coating. <i>Wellcome Open Research</i> , 2021, 6, 56.	1.8	7
94	Drivers of HIV-1 drug resistance to non-nucleoside reverse-transcriptase inhibitors (NNRTIs) in nine southern African countries: a modelling study. <i>BMC Infectious Diseases</i> , 2021, 21, 1042.	2.9	7
95	Coagulation factor V is a T-cell inhibitor expressed by leukocytes in COVID-19. <i>IScience</i> , 2022, 25, 103971.	4.1	7
96	Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to prevention. <i>Retrovirology</i> , 2013, 10, 82.	2.0	6
97	Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria. <i>AIDS Research and Therapy</i> , 2020, 17, 64.	1.7	5
98	A Declining CD4 Count and Diagnosis of HIV-Associated Hodgkin Lymphoma: Do Prior Clinical Symptoms and Laboratory Abnormalities Aid Diagnosis?. <i>PLoS ONE</i> , 2014, 9, e87442.	2.5	5
99	Innovative vaccine approachesâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2022, 1511, 59-86.	3.8	5
100	HIV-1 Evolutionary Dynamics under Nonsuppressive Antiretroviral Therapy. <i>MBio</i> , 2022, 13, e0026922.	4.1	5
101	Influenza pandemic plans: what about displaced populations?. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 256-257.	9.1	4
102	Sequential CCR5-Tropic HIV-1 Reactivation from Distinct Cellular Reservoirs following Perturbation of Elite Control. <i>PLoS ONE</i> , 2016, 11, e0158854.	2.5	4
103	Pretreatment HIV drug resistance in low- and middle-income countries. <i>Future Virology</i> , 2019, 14, 427-440.	1.8	3
104	Clinical recognition of meningococcal disease. <i>Lancet</i> , The, 2006, 367, 1395.	13.7	1
105	O07â€¦FXR antagonists as new agents for COVID19. , 2021, , .		1
106	Disengagement from HIV care and failure of second-line therapy in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, Publish Ahead of Print, .	2.1	1
107	Ultra Structural Characterisation of Tetherin - a Protein Capable of Preventing Viral Release from the Plasma Membrane. <i>Viruses</i> , 2010, 2, 987-994.	3.3	0
108	Point of care SARS-CoV-2 nucleic acid testing in schools improves school attendance. <i>Wellcome Open Research</i> , 0, 7, 8.	1.8	0